Connection
Connie Hess to Hydroxymethylglutaryl-CoA Reductase Inhibitors
This is a "connection" page, showing publications Connie Hess has written about Hydroxymethylglutaryl-CoA Reductase Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.835 |
|
|
|
-
Bonaca MP, Hess CN. ASCVD Risk and Statin Use in PAD: Implementing a New Approach to an Old Problem. J Am Coll Cardiol. 2020 07 21; 76(3):265-267.
Score: 0.536
-
Canonico ME, Hess CN, Cannon CP. In-Hospital Use of PCSK9 Inhibitors in the Post ACS Patient: What Does the Evidence Show? Curr Atheroscler Rep. 2023 07; 25(7):381-389.
Score: 0.163
-
Hess CN, Low Wang CC, Hiatt WR. PCSK9 Inhibitors: Mechanisms of Action, Metabolic Effects, and Clinical Outcomes. Annu Rev Med. 2018 01 29; 69:133-145.
Score: 0.111
-
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical Update: Cardiovascular Disease in Diabetes Mellitus: Atherosclerotic Cardiovascular Disease and Heart Failure in Type 2 Diabetes Mellitus - Mechanisms, Management, and Clinical Considerations. Circulation. 2016 Jun 14; 133(24):2459-502.
Score: 0.025